Title |
Association of a probiotic to a Helicobacter pylorieradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study
|
---|---|
Published in |
BMC Gastroenterology, March 2013
|
DOI | 10.1186/1471-230x-13-56 |
Pubmed ID | |
Authors |
Tomás Navarro-Rodriguez, Fernando Marcuz Silva, Ricardo Correa Barbuti, Rejane Mattar, Joaquim Prado Moraes-Filho, Maricê Nogueira de Oliveira, Cristina S Bogsan, Décio Chinzon, Jaime Natan Eisig |
Abstract |
The treatment for the eradication of Helicobacter pylori (H. pylori) is complex; full effectiveness is rarely achieved and it has many adverse effects. In developing countries, increased resistance to antibiotics and its cost make eradication more difficult. Probiotics can reduce adverse effects and improve the infection treatment efficacy.If the first-line therapy fails a second-line treatment using tetracycline, furazolidone and proton-pump inhibitors has been effective and low cost in Brazil; however it implies in a lot of adverse effects. The aim of this study was to minimize the adverse effects and increase the eradication rate applying the association of a probiotic compound to second-line therapy regimen. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 121 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 27 | 22% |
Student > Bachelor | 17 | 14% |
Researcher | 15 | 12% |
Other | 8 | 7% |
Student > Postgraduate | 7 | 6% |
Other | 20 | 17% |
Unknown | 27 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 41 | 34% |
Agricultural and Biological Sciences | 11 | 9% |
Immunology and Microbiology | 7 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
Biochemistry, Genetics and Molecular Biology | 5 | 4% |
Other | 19 | 16% |
Unknown | 31 | 26% |